The Experts below are selected from a list of 408 Experts worldwide ranked by ideXlab platform

Sabina Paglialunga - One of the best experts on this subject based on the ideXlab platform.

  • evidence for a direct effect of the nad precursor acipimox on muscle mitochondrial function in humans
    Diabetes, 2015
    Co-Authors: Tineke Van De Weijer, Esther Phielix, L. Bilet, Evan G. Williams, Eduardo R. Ropelle, Alessandra Bierwagen, Roshan Livingstone, Peter Nowotny, Lauren M. Sparks, Sabina Paglialunga
    Abstract:

    Recent preclinical studies showed the potential of nicotinamide adenine dinucleotide (NAD+) precursors to increase oxidative phosphorylation and improve metabolic health, but human data are lacking. We hypothesize that the Nicotinic Acid Derivative acipimox, an NAD+ precursor, would directly affect mitochondrial function independent of reductions in nonesterified fatty Acid (NEFA) concentrations. In a multicenter randomized crossover trial, 21 patients with type 2 diabetes (age 57.7 ± 1.1 years, BMI 33.4 ± 0.8 kg/m2) received either placebo or acipimox 250 mg three times daily dosage for 2 weeks. Acipimox treatment increased plasma NEFA levels (759 ± 44 vs. 1,135 ± 97 μmol/L for placebo vs. acipimox, P < 0.01) owing to a previously described rebound effect. As a result, skeletal muscle lipid content increased and insulin sensitivity decreased. Despite the elevated plasma NEFA levels, ex vivo mitochondrial respiration in skeletal muscle increased. Subsequently, we showed that acipimox treatment resulted in a robust elevation in expression of nuclear-encoded mitochondrial gene sets and a mitonuclear protein imbalance, which may indicate activation of the mitochondrial unfolded protein response. Further studies in C2C12 myotubes confirmed a direct effect of acipimox on NAD+ levels, mitonuclear protein imbalance, and mitochondrial oxidative capacity. To the best of our knowledge, this study is the first to demonstrate that NAD+ boosters can also directly affect skeletal muscle mitochondrial function in humans.

  • Evidence for a Direct Effect of the NAD(+) Precursor Acipimox on Muscle Mitochondrial Function in Humans
    Diabetes, 2014
    Co-Authors: Tineke Van De Weijer, Esther Phielix, L. Bilet, Evan G. Williams, Eduardo R. Ropelle, Alessandra Bierwagen, Roshan Livingstone, Peter Nowotny, Lauren M. Sparks, Sabina Paglialunga
    Abstract:

    Recent preclinical studies showed the potential of nicotinamide adenine dinucleotide (NAD+) precursors to increase oxidative phosphorylation and improve metabolic health, but human data are lacking. We hypothesize that the Nicotinic Acid Derivative acipimox, an NAD+ precursor, would directly affect mitochondrial function independent of reductions in nonesterified fatty Acid (NEFA) concentrations. In a multicenter randomized crossover trial, 21 patients with type 2 diabetes (age 57.7 ± 1.1 years, BMI 33.4 ± 0.8 kg/m2) received either placebo or acipimox 250 mg three times daily dosage for 2 weeks. Acipimox treatment increased plasma NEFA levels (759 ± 44 vs. 1,135 ± 97 μmol/L for placebo vs. acipimox, P < 0.01) owing to a previously described rebound effect. As a result, skeletal muscle lipid content increased and insulin sensitivity decreased. Despite the elevated plasma NEFA levels, ex vivo mitochondrial respiration in skeletal muscle increased. Subsequently, we showed that acipimox treatment resulted in a robust elevation in expression of nuclear-encoded mitochondrial gene sets and a mitonuclear protein imbalance, which may indicate activation of the mitochondrial unfolded protein response. Further studies in C2C12 myotubes confirmed a direct effect of acipimox on NAD+ levels, mitonuclear protein imbalance, and mitochondrial oxidative capacity. To the best of our knowledge, this study is the first to demonstrate that NAD+ boosters can also directly affect skeletal muscle mitochondrial function in humans.

Eric P Krenning - One of the best experts on this subject based on the ideXlab platform.

  • feasibility and image quality of dual isotope spect using 18f fdg and 99mtc tetrofosmin after acipimox administration
    The Journal of Nuclear Medicine, 2003
    Co-Authors: Boen L R Kam, Roelf Valkema, Don Poldermans, Jeroen J Bax, Ambroos E M Reijs, Riccardo Rambaldi, Eric Boersma, Trinet Rietveld, Jos R T C Roelandt, Eric P Krenning
    Abstract:

    Currently, with the rapidly increasing number of patients with heart failure due to chronic coronary artery disease, the need for viability studies to guide treatment in these patients is increasing. The most accurate method for viability assessment is metabolic imaging with 18F-FDG with PET or SPECT. To obtain excellent image quality in all patients, the 18F-FDG studies should be performed during hyperinsulinemic euglycemic clamping. However, this approach is time-consuming and is not feasible in busy nuclear medicine laboratories. Recently, the use of a Nicotinic Acid Derivative, acipimox, has been suggested, but limited data are available on the image quality of the 18F-FDG studies using this approach. Methods: We evaluated the feasibility and image quality of 18F-FDG SPECT (with dual-isotope simultaneous acquisition (DISA) using 99mTc-tetrofosmin to assess perfusion) after acipimox administration in 50 nondiabetic patients. The image quality of both 18F-FDG and 99mTc-tetrofosmin was assessed visually and quantitatively using myocardium-to-blood-pool (M/B) ratios as a measure of target-to-background ratio. The image quality and diagnostic value of DISA 99mTc-tetrofosmin SPECT was compared with standard 99mTc-tetrofosmin SPECT at baseline. Results: After acipimox administration, the plasma levels of free fatty Acids were extremely low (68 ± 89 nmol/L). No severe side effects were observed, only paroxysmal flushing. The 18F-FDG image quality was good in 46 patients (92%) and moderate but still interpretable in the other 4 patients (8%). The clinical information of the baseline 99mTc-tetrofosmin SPECT was retained in the DISA 99mTc-tetrofosmin SPECT images because we did observe no substantial fill-in of perfusion defects by high 18F-FDG uptake in the same segment. Conclusion: Cardiac 18F-FDG SPECT after acipimox is safe and resulted consistently in good image quality; this simple approach may be the method of choice for routine cardiac metabolic imaging.

Jeroen J Bax - One of the best experts on this subject based on the ideXlab platform.

  • feasibility and image quality of dual isotope spect using 18f fdg and 99mtc tetrofosmin after acipimox administration
    The Journal of Nuclear Medicine, 2003
    Co-Authors: Boen L R Kam, Roelf Valkema, Don Poldermans, Jeroen J Bax, Ambroos E M Reijs, Riccardo Rambaldi, Eric Boersma, Trinet Rietveld, Jos R T C Roelandt, Eric P Krenning
    Abstract:

    Currently, with the rapidly increasing number of patients with heart failure due to chronic coronary artery disease, the need for viability studies to guide treatment in these patients is increasing. The most accurate method for viability assessment is metabolic imaging with 18F-FDG with PET or SPECT. To obtain excellent image quality in all patients, the 18F-FDG studies should be performed during hyperinsulinemic euglycemic clamping. However, this approach is time-consuming and is not feasible in busy nuclear medicine laboratories. Recently, the use of a Nicotinic Acid Derivative, acipimox, has been suggested, but limited data are available on the image quality of the 18F-FDG studies using this approach. Methods: We evaluated the feasibility and image quality of 18F-FDG SPECT (with dual-isotope simultaneous acquisition (DISA) using 99mTc-tetrofosmin to assess perfusion) after acipimox administration in 50 nondiabetic patients. The image quality of both 18F-FDG and 99mTc-tetrofosmin was assessed visually and quantitatively using myocardium-to-blood-pool (M/B) ratios as a measure of target-to-background ratio. The image quality and diagnostic value of DISA 99mTc-tetrofosmin SPECT was compared with standard 99mTc-tetrofosmin SPECT at baseline. Results: After acipimox administration, the plasma levels of free fatty Acids were extremely low (68 ± 89 nmol/L). No severe side effects were observed, only paroxysmal flushing. The 18F-FDG image quality was good in 46 patients (92%) and moderate but still interpretable in the other 4 patients (8%). The clinical information of the baseline 99mTc-tetrofosmin SPECT was retained in the DISA 99mTc-tetrofosmin SPECT images because we did observe no substantial fill-in of perfusion defects by high 18F-FDG uptake in the same segment. Conclusion: Cardiac 18F-FDG SPECT after acipimox is safe and resulted consistently in good image quality; this simple approach may be the method of choice for routine cardiac metabolic imaging.

  • safety and feasibility of cardiac fdg spect following oral administration of acipimox a Nicotinic Acid Derivative comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients
    Journal of Nuclear Cardiology, 2002
    Co-Authors: Jeroen J Bax, Don Poldermans, Eric Boersma, Frans C Visser, Arthur Van Lingen, Abdou Elhendy, Gerrit W Sloof, Cees A Visser
    Abstract:

    Background Image quality of cardiac fluorine-18-deoxyglucose (FDG) studies is highly dependent on the metabolic conditions during the study; hyperinsulinemic euglycemic clamping ensures adequate image quality. However, the approach is time-consuming. Data in a small number of patients suggest that oral administration of a Nicotinic Acid Derivative (Acipimox, 250 mg; Byk, The Netherlands) results in good image quality.

Don Poldermans - One of the best experts on this subject based on the ideXlab platform.

  • feasibility and image quality of dual isotope spect using 18f fdg and 99mtc tetrofosmin after acipimox administration
    The Journal of Nuclear Medicine, 2003
    Co-Authors: Boen L R Kam, Roelf Valkema, Don Poldermans, Jeroen J Bax, Ambroos E M Reijs, Riccardo Rambaldi, Eric Boersma, Trinet Rietveld, Jos R T C Roelandt, Eric P Krenning
    Abstract:

    Currently, with the rapidly increasing number of patients with heart failure due to chronic coronary artery disease, the need for viability studies to guide treatment in these patients is increasing. The most accurate method for viability assessment is metabolic imaging with 18F-FDG with PET or SPECT. To obtain excellent image quality in all patients, the 18F-FDG studies should be performed during hyperinsulinemic euglycemic clamping. However, this approach is time-consuming and is not feasible in busy nuclear medicine laboratories. Recently, the use of a Nicotinic Acid Derivative, acipimox, has been suggested, but limited data are available on the image quality of the 18F-FDG studies using this approach. Methods: We evaluated the feasibility and image quality of 18F-FDG SPECT (with dual-isotope simultaneous acquisition (DISA) using 99mTc-tetrofosmin to assess perfusion) after acipimox administration in 50 nondiabetic patients. The image quality of both 18F-FDG and 99mTc-tetrofosmin was assessed visually and quantitatively using myocardium-to-blood-pool (M/B) ratios as a measure of target-to-background ratio. The image quality and diagnostic value of DISA 99mTc-tetrofosmin SPECT was compared with standard 99mTc-tetrofosmin SPECT at baseline. Results: After acipimox administration, the plasma levels of free fatty Acids were extremely low (68 ± 89 nmol/L). No severe side effects were observed, only paroxysmal flushing. The 18F-FDG image quality was good in 46 patients (92%) and moderate but still interpretable in the other 4 patients (8%). The clinical information of the baseline 99mTc-tetrofosmin SPECT was retained in the DISA 99mTc-tetrofosmin SPECT images because we did observe no substantial fill-in of perfusion defects by high 18F-FDG uptake in the same segment. Conclusion: Cardiac 18F-FDG SPECT after acipimox is safe and resulted consistently in good image quality; this simple approach may be the method of choice for routine cardiac metabolic imaging.

  • safety and feasibility of cardiac fdg spect following oral administration of acipimox a Nicotinic Acid Derivative comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients
    Journal of Nuclear Cardiology, 2002
    Co-Authors: Jeroen J Bax, Don Poldermans, Eric Boersma, Frans C Visser, Arthur Van Lingen, Abdou Elhendy, Gerrit W Sloof, Cees A Visser
    Abstract:

    Background Image quality of cardiac fluorine-18-deoxyglucose (FDG) studies is highly dependent on the metabolic conditions during the study; hyperinsulinemic euglycemic clamping ensures adequate image quality. However, the approach is time-consuming. Data in a small number of patients suggest that oral administration of a Nicotinic Acid Derivative (Acipimox, 250 mg; Byk, The Netherlands) results in good image quality.

Eric Boersma - One of the best experts on this subject based on the ideXlab platform.

  • feasibility and image quality of dual isotope spect using 18f fdg and 99mtc tetrofosmin after acipimox administration
    The Journal of Nuclear Medicine, 2003
    Co-Authors: Boen L R Kam, Roelf Valkema, Don Poldermans, Jeroen J Bax, Ambroos E M Reijs, Riccardo Rambaldi, Eric Boersma, Trinet Rietveld, Jos R T C Roelandt, Eric P Krenning
    Abstract:

    Currently, with the rapidly increasing number of patients with heart failure due to chronic coronary artery disease, the need for viability studies to guide treatment in these patients is increasing. The most accurate method for viability assessment is metabolic imaging with 18F-FDG with PET or SPECT. To obtain excellent image quality in all patients, the 18F-FDG studies should be performed during hyperinsulinemic euglycemic clamping. However, this approach is time-consuming and is not feasible in busy nuclear medicine laboratories. Recently, the use of a Nicotinic Acid Derivative, acipimox, has been suggested, but limited data are available on the image quality of the 18F-FDG studies using this approach. Methods: We evaluated the feasibility and image quality of 18F-FDG SPECT (with dual-isotope simultaneous acquisition (DISA) using 99mTc-tetrofosmin to assess perfusion) after acipimox administration in 50 nondiabetic patients. The image quality of both 18F-FDG and 99mTc-tetrofosmin was assessed visually and quantitatively using myocardium-to-blood-pool (M/B) ratios as a measure of target-to-background ratio. The image quality and diagnostic value of DISA 99mTc-tetrofosmin SPECT was compared with standard 99mTc-tetrofosmin SPECT at baseline. Results: After acipimox administration, the plasma levels of free fatty Acids were extremely low (68 ± 89 nmol/L). No severe side effects were observed, only paroxysmal flushing. The 18F-FDG image quality was good in 46 patients (92%) and moderate but still interpretable in the other 4 patients (8%). The clinical information of the baseline 99mTc-tetrofosmin SPECT was retained in the DISA 99mTc-tetrofosmin SPECT images because we did observe no substantial fill-in of perfusion defects by high 18F-FDG uptake in the same segment. Conclusion: Cardiac 18F-FDG SPECT after acipimox is safe and resulted consistently in good image quality; this simple approach may be the method of choice for routine cardiac metabolic imaging.

  • safety and feasibility of cardiac fdg spect following oral administration of acipimox a Nicotinic Acid Derivative comparison of image quality with hyperinsulinemic euglycemic clamping in nondiabetic patients
    Journal of Nuclear Cardiology, 2002
    Co-Authors: Jeroen J Bax, Don Poldermans, Eric Boersma, Frans C Visser, Arthur Van Lingen, Abdou Elhendy, Gerrit W Sloof, Cees A Visser
    Abstract:

    Background Image quality of cardiac fluorine-18-deoxyglucose (FDG) studies is highly dependent on the metabolic conditions during the study; hyperinsulinemic euglycemic clamping ensures adequate image quality. However, the approach is time-consuming. Data in a small number of patients suggest that oral administration of a Nicotinic Acid Derivative (Acipimox, 250 mg; Byk, The Netherlands) results in good image quality.